{"success":true,"data":{"pressRelease":{"id":"133776","rtpr_id":"nGNX8yVQMx","ticker":"DSGN","exchange":"NASDAQ","all_tickers":["DSGN"],"title":"Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference","author":"Globe Newswire","published_at":"2026-09-02T12:00:00.943Z","article_body":"CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc.\n(Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments\nfor serious degenerative genetic diseases, today announced that management\nwill participate in a fireside chat during the 2026 Cantor Fitzgerald Global\nHealthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New\nYork.\n\nA live webcast of the fireside chat will be available here\n(https://www.globenewswire.com/Tracker?data=AQEsKuT5zqdztBjQxob4So6mATBmxwCsedHTUpYAB13qwaiYKayI3KWOZukOsdeIQKFHiDLEwoStvYLbPia6MvZ8OqifZNVKWcjmB0FP8yyXK1eSuM3ggIcZAEGZ_AYo6h3LjokAntDKf7epUGOHYA==)\nand in the investors section of the company’s website at\nwww.designtx.com.The webcast will be archived for at least 30 days following\neach presentation.\n\nAbout Design Therapeutics\nDesign Therapeutics is a clinical-stage biotechnology company developing a new\nclass of therapies based on its platform of GeneTAC(®) gene targeted chimera\nsmall molecules. The company’s GeneTAC(®) molecules are designed to either\ndial up or dial down the expression of a specific disease-causing gene to\naddress the underlying cause of disease. In addition to its clinical-stage\nGeneTAC(®) programs, DT-216P2, in development for patients with Friedreich\nataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for\nmyotonic dystrophy type-1, the company is advancing a program in\nHuntington’s disease. Discovery efforts are underway for multiple genomic\nmedicines. For more information, please visit designtx.com.\n\nContact:\nRenee Leck, THRUST \nrenee@thrustsc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bbfe687d-5236-42ea-8012-8ab435c6914d)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8yVQMx","title":"Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference","author":"Globe Newswire","ticker":"DSGN","created":"2026-09-02T12:00:00.943Z","tickers":["DSGN"],"exchange":"NASDAQ","article_body":"CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc.\n(Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments\nfor serious degenerative genetic diseases, today announced that management\nwill participate in a fireside chat during the 2026 Cantor Fitzgerald Global\nHealthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New\nYork.\n\nA live webcast of the fireside chat will be available here\n(https://www.globenewswire.com/Tracker?data=AQEsKuT5zqdztBjQxob4So6mATBmxwCsedHTUpYAB13qwaiYKayI3KWOZukOsdeIQKFHiDLEwoStvYLbPia6MvZ8OqifZNVKWcjmB0FP8yyXK1eSuM3ggIcZAEGZ_AYo6h3LjokAntDKf7epUGOHYA==)\nand in the investors section of the company’s website at\nwww.designtx.com.The webcast will be archived for at least 30 days following\neach presentation.\n\nAbout Design Therapeutics\nDesign Therapeutics is a clinical-stage biotechnology company developing a new\nclass of therapies based on its platform of GeneTAC(®) gene targeted chimera\nsmall molecules. The company’s GeneTAC(®) molecules are designed to either\ndial up or dial down the expression of a specific disease-causing gene to\naddress the underlying cause of disease. In addition to its clinical-stage\nGeneTAC(®) programs, DT-216P2, in development for patients with Friedreich\nataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for\nmyotonic dystrophy type-1, the company is advancing a program in\nHuntington’s disease. Discovery efforts are underway for multiple genomic\nmedicines. For more information, please visit designtx.com.\n\nContact:\nRenee Leck, THRUST \nrenee@thrustsc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bbfe687d-5236-42ea-8012-8ab435c6914d)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T12:00:00.987762188Z","server_sent_at_ms":1788350400987},"received_at":"2026-09-02T12:00:01.077Z","source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355100/0/en/design-therapeutics-to-participate-in-2026-cantor-fitzgerald-global-healthcare-conference.html"},"analysis":{"id":"122667","press_release_id":"133776","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Design Therapeutics (DSGN) announced management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.\n\nA live webcast will be available via the company's investor relations website, with the archive accessible for at least 30 days following the presentation.\n\nThe release contains no new clinical or financial data; it restates the pipeline of GeneTAC programs, including DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and a Huntington's disease program.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference-participation notice with no new data -- suppress or note only for the September 9 fireside chat calendar."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Renee Leck","role":"media contact (THRUST)"}],"products":["GeneTAC","DT-216P2","DT-168","DT-818"],"companies":[{"name":"Design Therapeutics, Inc.","ticker":"DSGN","relationship":"filer"},{"name":"Cantor Fitzgerald","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations announcement of management participation in an upcoming conference fireside chat. No new clinical, financial, or strategic information disclosed."},"tickerRelevance":{"others":[],"primary":"DSGN"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-investor-conference","issuerAuthored":true,"householdBrandBoost":0,"retailFavoriteBoost":0,"newInformationContent":"none -- boilerplate IR scheduling announcement"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Design Therapeutics (DSGN) announced management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.\n\nA live webcast will be available via the company's investor relations website, with the archive accessible for at least 30 days following the presentation.\n\nThe release contains no new clinical or financial data; it restates the pipeline of GeneTAC programs, including DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and a Huntington's disease program.","key_figures":{},"named_entities":{"people":[{"name":"Renee Leck","role":"media contact (THRUST)"}],"products":["GeneTAC","DT-216P2","DT-168","DT-818"],"companies":[{"name":"Design Therapeutics, Inc.","ticker":"DSGN","relationship":"filer"},{"name":"Cantor Fitzgerald","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T12:56:59.584Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-investor-conference","issuerAuthored":true,"householdBrandBoost":0,"retailFavoriteBoost":0,"newInformationContent":"none -- boilerplate IR scheduling announcement"}},"durationMs":135308,"modelName":"glm-4.7"}}